Your email has been successfully added to our mailing list.

×
-0.000621118012422457 -0.00310559006211185 -0.00124223602484469 0 -0.0248447204968944 -0.0338509316770186 -0.0574534161490684 -0.0535714285714286
Stock impact report

What Aimmune's Peanut Allergy Drug Approval Means for the Rest of the Pipeline [The Motley Fool]

AIMMUNE THERAPEUTICS (AIMT) 
Last aimmune therapeutics earnings: 2/27 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.aimmune.com/corporate-profile
Company Research Source: The Motley Fool
Aimmune Therapeutics ( NASDAQ:AIMT Aimmune's Palforzia is the first approved drug to treat peanut allergies, and the first approved treatment for any kind of food allergy, giving it a home run that the company, patients, and investors can all celebrate. Since Aimmune's pipeline is all about treating food allergies, this approval may be viewed as a positive sign showing the company's method can deliver. Image source: Getty Images. Why is everyone going nuts? Any nod from the FDA is good news for a company, but some investors might be wondering why the Palforzia approval has stirred up so much excitement. From both medical and financial perspectives, the opportunity is significant. Clearly, with the lack of approved treatments prior to Palforzia, therapy for peanut allergy was an unmet need. And as the following statistics show, it's not a small niche market. Peanut allergies are the most prevalent among children in the U.S., affecting about . million adolescents, a 08 study in the jour Show less Read more
Impact Snapshot
Event Time:
AIMT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for AIMT alerts
Opt-in for
AIMT alerts

from News Quantified
Opt-in for
AIMT alerts

from News Quantified